Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer

Status unconfirmed · Phase 2

Conditions studied: Head and Neck Cancer

In brief

RATIONALE: Drugs such as rosiglitazone may make tumor cells more sensitive to radioactive iodine. PURPOSE: This phase II trial is studying how well rosiglitazone works in treating patients with locoregionally extensive or metastatic thyroid cancer.

Key facts

Study ID

NCT00098852

Run by

University of California, San Francisco

People needed

25

Starts

2004-10-01

Last updated by the study team

2014-01-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.